HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Heimburger O, Martus G, Wilkie ME, et al.

Steady Concentration Peritoneal Dialysis Increases Ultrafiltration and Sodium Removal Compared with Continuous Ambulatory Peritoneal Dialysis (CAPD)

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:51A 2020


Fluid and sodium removal (NaR) may be a challenge during glucose-based PD, leading to increased use of high glucose solutions to maintain sufficient fluid removal. This may lead to increased sodium sieving, resulting in reduced NaR. Carry Life® UF uses steady concentration PD (SCPD), where the intraperitoneal (IP) glucose concentration is maintained by infusion of glucose to provide a continuous ultrafiltration (UF) throughout the dwell. The present study investigated the effect of Carry Life® UF vs. CAPD regarding UF, NaR and glucose absorption.


Eight stable PD patients were included in the study. Subjects were treated with 5-hour Carry Life® UF treatments using three different glucose doses (11, 14, 20 g/h). An initial fill with 1.5 l, 1.36% glucose PD solution was used. A small volume of dialysate was drained hourly to avoid overfill. A 4-hour peritoneal equilibration test (PET) (2.0 l, 2.27% glucose) served as control. Data expressed as mean±SD, statistical analysis using ANOVA.


UF volumes were significantly increased during Carry Life® UF treatments (646±256, 739±312, 863±380 ml for 11, 14 and 20 g/h) vs. PET (162±242 ml, p<0.01). NaR increased significantly during Carry Life® UF treatments (86±27, 92±33 110±37 mmol/dwell for 11, 14 and 20 g glucose/h) compared to PET (22±33 mmol/dwell, p<0.001).


SCPD performed with Carry Life® UF maintained a stable IP glucose concentration during the treatment (figure a) which generated significantly higher UF volumes compared to PET. During the Carry Life UF treatments glucose was used more efficiently, particularly for the two lowest doses, in comparison to PET (figure b). In summary, SCPD using Carry Life® UF increases the efficiency of PD compared to standard, glucose-based CAPD with respect to UF and NaR.

IP glucose concentration in g/l during treatments (a).
UF efficiency expressed as UF volume in ml per gram of glucose absorbed during treatments, *p<0.05, **p<0.01 (b).

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.